Apollo Hospitals Enterprises Ltd.
Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, oncology, neurosciences, gastroenterology, orthopedics, urology, organ transplantation, pulmonology, obstetrics and gynecology, internal medicine, vascular surgery, pediatrics, cosmetology, emergency medicine, bariatric surgery, general surgery, colorectal surgery, dentistry, nephrology, dermatology, endocrinology, preventive medicine, interventional radiology, ophthalmology, and integrative medicine, as well as robotic surgery and genomics. The company also provides project consultancy, medical educational institutes, Medvarsity for e-learning, and research services, as well as acts as an agent for life, general, and health insurance. In addition, it operates hospitals, pharmacies, primary care clinics, and diagnostic centers; short stay facilities, boutique birthing centers, multi-specialty clinics, dental and dialysis facilities, and preventive care; day surgery, diabetes management, and cradle and fertility centers; and Apollo 24/7, a digital health mobile platform that provides teleconsultations, online pharmacy deliveries, home diagnostics, and insurance services. Further, the company engages in the business of bio-banking of tissues. It serves patients, corporate clients, and the government and public sectors. Apollo Hospitals Enterprise Limited was incorporated in 1979 and is based in Chennai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Nov has averaged the highest return (+9.2%); Jan the lowest (-2.5%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.2%Neutral MonthJan 2026: -1.17% | +12.4%Positive MonthFeb 2026: +12.36% | -5.0%Negative MonthMar 2026: -5.01% | +2.8%Positive MonthApr 2026: +2.84% | +9.4%Positive MonthMay 2026: +9.43% | +3.9%Positive MonthJun 2026: +3.93% | +3.1%Positive MonthJul 2026: +3.13% | -1.9%*Neutral MonthAug 2026: -1.90% | β | β | β | β |
| 2025 | -6.6%Negative MonthJan 2025: -6.57% | -11.2%Negative MonthFeb 2025: -11.19% | +9.4%Positive MonthMar 2025: +9.42% | +5.1%Positive MonthApr 2025: +5.13% | -1.2%Neutral MonthMay 2025: -1.20% | +5.3%Positive MonthJun 2025: +5.30% | +3.5%Positive MonthJul 2025: +3.48% | +1.5%Neutral MonthAug 2025: +1.49% | -2.6%Negative MonthSep 2025: -2.58% | +3.6%Positive MonthOct 2025: +3.63% | -4.5%Negative MonthNov 2025: -4.52% | -4.0%Negative MonthDec 2025: -3.95% |
| 2024 | +11.5%Positive MonthJan 2024: +11.49% | -4.0%Negative MonthFeb 2024: -3.96% | +4.0%Positive MonthMar 2024: +4.05% | -6.4%Negative MonthApr 2024: -6.39% | -1.8%Neutral MonthMay 2024: -1.79% | +5.9%Positive MonthJun 2024: +5.92% | +7.1%Positive MonthJul 2024: +7.10% | +4.6%Positive MonthAug 2024: +4.59% | +3.9%Positive MonthSep 2024: +3.85% | -2.4%Negative MonthOct 2024: -2.43% | -2.7%Negative MonthNov 2024: -2.72% | +6.8%Positive MonthDec 2024: +6.80% |
| 2023 | -5.0%Negative MonthJan 2023: -4.98% | +3.4%Positive MonthFeb 2023: +3.42% | -2.1%Negative MonthMar 2023: -2.09% | +4.9%Positive MonthApr 2023: +4.89% | +2.3%Positive MonthMay 2023: +2.28% | +10.2%Positive MonthJun 2023: +10.23% | +4.9%Positive MonthJul 2023: +4.87% | -9.8%Negative MonthAug 2023: -9.83% | +6.6%Positive MonthSep 2023: +6.62% | -6.2%Negative MonthOct 2023: -6.20% | +14.8%Positive MonthNov 2023: +14.76% | +3.1%Positive MonthDec 2023: +3.09% |
| 2022 | -11.1%Negative MonthJan 2022: -11.09% | +7.7%Positive MonthFeb 2022: +7.74% | -5.9%Negative MonthMar 2022: -5.94% | -1.3%Neutral MonthApr 2022: -1.30% | -10.7%Negative MonthMay 2022: -10.74% | -7.5%Negative MonthJun 2022: -7.52% | +14.5%Positive MonthJul 2022: +14.47% | +2.5%Positive MonthAug 2022: +2.47% | +1.5%Neutral MonthSep 2022: +1.55% | +3.1%Positive MonthOct 2022: +3.08% | +4.8%Positive MonthNov 2022: +4.76% | -5.4%Negative MonthDec 2022: -5.38% |
| 2021 | β | β | β | β | β | +14.1%Positive MonthJun 2021: +14.14% | +11.5%Positive MonthJul 2021: +11.50% | +23.2%Positive MonthAug 2021: +23.16% | -9.7%Negative MonthSep 2021: -9.74% | -5.0%Negative MonthOct 2021: -4.99% | +33.6%Positive MonthNov 2021: +33.60% | -11.9%Negative MonthDec 2021: -11.95% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 6 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ8.20 K Cr | β | βΉ1.30 K Cr | β | β | 14.8% | 12.8% | 28.3% |
| Mar 2024 | βΉ7.27 K Cr | β | βΉ1.01 K Cr | β | β | 13.1% | 11.5% | -6.9% |
| Mar 2023 | βΉ6.53 K Cr | β | βΉ1.08 K Cr | β | β | 15.7% | 7.0% | 63.2% |
| Mar 2022 | βΉ6.10 K Cr | β | βΉ665.00 Cr | β | β | 10.9% | 31.0% | 533.3% |
| Mar 2021 | βΉ4.65 K Cr | β | βΉ105.00 Cr | β | β | 2.0% | -52.5% | -77.7% |
| Mar 2020 | βΉ9.79 K Cr | β | βΉ470.00 Cr | β | β | 11.8% | 17.5% | 55.1% |
| Mar 2019 | βΉ8.34 K Cr | β | βΉ303.00 Cr | β | β | 7.8% | 16.1% | 30.0% |
| Mar 2018 | βΉ7.18 K Cr | β | βΉ233.00 Cr | β | β | 6.3% | 14.0% | -18.2% |
| Mar 2017 | βΉ6.30 K Cr | β | βΉ285.00 Cr | β | β | 8.0% | 14.1% | -14.7% |
| Mar 2016 | βΉ5.52 K Cr | β | βΉ334.00 Cr | β | β | 10.1% | 21.6% | -3.7% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 3,835 | 4,543 | 5,523 | 6,301 | 7,183 | 8,337 | 9,794 | 4,654 | 6,098 | 6,525 | 7,274 | 8,202 | 8,654 |
| Total Expenses | 3,218 | 3,862 | 4,776 | 5,527 | 6,348 | 7,314 | 8,377 | 3,938 | 4,677 | 4,831 | 5,476 | 6,152 | 6,482 |
| EBIT / Operating Profit | 617 | 681 | 748 | 774 | 835 | 1,022 | 1,418 | 715 | 1,421 | 1,694 | 1,798 | 2,050 | 2,172 |
| OPM % | 16% | 15% | 14% | 12% | 12% | 12% | 14% | 15% | 23% | 26% | 25% | 25% | 25% |
| Other Income | 20 | 28 | 4 | 26 | 7 | 8 | 173 | 137 | 131 | 139 | 180 | 342 | 373 |
| Finance Costs | 87 | 83 | 134 | 200 | 240 | 268 | 426 | 340 | 244 | 239 | 250 | 254 | 242 |
| Depreciation & Amortisation | 129 | 158 | 200 | 241 | 272 | 300 | 482 | 421 | 363 | 367 | 399 | 449 | 484 |
| Profit Before Tax | 420 | 467 | 417 | 359 | 330 | 462 | 682 | 91 | 945 | 1,228 | 1,329 | 1,688 | 1,820 |
| Tax % | 21% | 26% | 20% | 21% | 29% | 35% | 31% | -15% | 30% | 12% | 24% | 23% | - |
| Net Profit / PAT | 331 | 347 | 334 | 285 | 233 | 303 | 470 | 105 | 665 | 1,085 | 1,010 | 1,296 | 1,402 |
| EPS (βΉ) | 23.77 | 24.91 | 24 | 20.50 | 16.76 | 21.76 | 33.80 | 7.30 | 46.26 | 75.45 | 70.28 | 90.16 | 97.49 |
| Dividend Payout % | 24% | 23% | 25% | 29% | 30% | 28% | 18% | 41% | 25% | 20% | 23% | 14% | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprises Ltd.this co. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Lupin Ltd | βΉ99.47 K Cr | βΉ16.97 K Cr | 18.60 | 3.66 | 27.43 | 15.7% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
